1. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
- Author
-
Kantarjian, Hagop M, Begna, Kebede H, Altman, Jessica K, Goldberg, Stuart L, Sekeres, Mikkael A, Strickland, Stephen A, Arellano, Martha L, Claxton, David F, Baer, Maria R, Gautier, Marc, Berman, Ellin, Seiter, Karen, Solomon, Scott R, Schiller, Gary J, Luger, Selina M, Butrym, Aleksandra, Gaidano, Gianluca, Thomas, Xavier G, Montesinos, Pau, Rizzieri, David A, Quick, Donald P, Venugopal, Parameswaran, Gaur, Rakesh, Maness, Lori J, Kadia, Tapan M, Ravandi, Farhad, Buyse, Marc E, and Chiao, Judy H
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Hematology ,Clinical Trials and Supportive Activities ,Clinical Research ,Rare Diseases ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Aged ,Arabinonucleosides ,Azacitidine ,Cytosine ,Decitabine ,Humans ,Leukemia ,Myeloid ,Acute ,Treatment Outcome ,acute myeloid leukemia ,decitabine ,hypomethylation ,sapacitabine ,therapy ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low-intensity therapy, to elderly patients with newly diagnosed AML.MethodsThis randomized, open-label, phase 3 study (SEAMLESS) was conducted at 87 sites in 11 countries. Patients aged ≥70 years who were not candidates for or chose not to receive standard induction chemotherapy were randomized 1:1 to arm A (decitabine in alternating cycles with sapacitabine) received 1-hour intravenous infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 8 weeks (first cycle and subsequent odd cycles) and sapacitabine 300 mg twice daily on 3 consecutive days per week for 2 weeks every 8 weeks (second cycle and subsequent even cycles) or to control arm C who received 1-hour infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 4 weeks. Prior hypomethylating agent therapy for preexisting myelodysplastic syndromes or myeloproliferative neoplasms was an exclusion criterion. Randomization was stratified by antecedent myelodysplastic syndromes or myeloproliferative neoplasms, white blood cell count (
- Published
- 2021